Cochrane Abstracts
Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Phosphodiesterase 5 Inhibitors (PDE5i) for the Treatment of Raynaud's Phenomenon." Cochrane Abstracts, John Wiley & Sons, Inc, 2026. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/440611/all/Phosphodiesterase_5_inhibitors__PDE5i__for_the_treatment_of_Raynaud&apos.
Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon. Cochrane Abstracts. John Wiley & Sons, Inc; 2026. https://evidence.unboundmedicine.com/evidence/view/Cochrane/440611/all/Phosphodiesterase_5_inhibitors__PDE5i__for_the_treatment_of_Raynaud&apos. Accessed February 15, 2026.
Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon. (2026). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/440611/all/Phosphodiesterase_5_inhibitors__PDE5i__for_the_treatment_of_Raynaud&apos
Phosphodiesterase 5 Inhibitors (PDE5i) for the Treatment of Raynaud's Phenomenon [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2026. [cited 2026 February 15]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/440611/all/Phosphodiesterase_5_inhibitors__PDE5i__for_the_treatment_of_Raynaud&apos.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon
ID - 440611
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/440611/all/Phosphodiesterase_5_inhibitors__PDE5i__for_the_treatment_of_Raynaud&apos
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
